Recruiting · registry status

Studying a Parkinson’s medicine in everyday care in Germany

Researchers are following people receiving foslevodopa and foscarbidopa in routine care to assess how the treatment works as Parkinson’s becomes more advanced.

Learning by observing or collecting information · Study reference: NCT06916507

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Who can join?

Ages 18 years to 67 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease * Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label * Participant must be an adult male or female, 18-67 years of age * Time since beginning of motor fluctuations \<= 5 years * The Hoehn and Yahr (H\&Y) stage \<= 3 * Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in this study Exclusion Criteria: * Previous Exposure to any device-aided therapy (DAT). * Any condition included in the contraindications section of the approved local LDp/CDp label. * Participants with Mini mental state examination (MMSE) score \< 24

Full study name & original research details

Official study title

German Real-World Evidence Study on the Effectiveness of Foslevodopa/Foscarbidopa at Initial Stages of Advanced Parkinson's Disease: Motor Symptoms, Quality of Life, Psychosocial Functioning and Work Ability

Short title used by the registry

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

Original description

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa/ foslevodopa is in treating German adult participants at initial stages of advanced Parkinson's disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 125 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 20 sites in Germany. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 12 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Conditions reported: Parkinson's Disease

Study type: Observational
Interventions: Not reported
Phases: Not reported
Sponsor: AbbVie
Start date reported by registry: 2025-05-05 (actual)

Registry updated: 2026-10-02 · Status last verified by the registry submitter: 2026-09

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Medical Information Germany · 49 611 1720 1520 · medinfo.germany@abbvie.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Kliniken Schmieder - Allensbach /ID# 285402

Allensbach, Baden-Wurttemberg, Germany

Recruiting

Universitaetsklinikum Heidelberg /ID# 274164

Heidelberg, Baden-Wurttemberg, Germany

Recruiting

Universitaetsklinikum Tuebingen /ID# 275828

Tübingen, Baden-Wurttemberg, Germany

Recruiting

Praxis Prof. Kassubek/Prof. Riecker /ID# 274165

Ulm, Baden-Wurttemberg, Germany

Recruiting

Parkinson-Klinik Ortenau GmbH&Co KG /ID# 274161

Wolfach, Baden-Wurttemberg, Germany

Recruiting

Universitaetsklinikum Erlangen /ID# 280831

Erlangen, Bavaria, Germany

Recruiting

Klinikum Ingolstadt /ID# 280573

Ingolstadt, Bavaria, Germany

Recruiting

Klinikum der Universitaet Muenchen Grosshadern /ID# 274168

Munich, Bavaria, Germany

Recruiting

Klinikum Ernst von Bergmann /ID# 274176

Potsdam, Brandenburg, Germany

Recruiting

Universitaetskliniken Giessen und Marburg /ID# 274224

Marburg, Hesse, Germany

Recruiting

Knappschaftskrankenhaus Bottrop /ID# 274284

Bottrop, North Rhine-Westphalia, Germany

Recruiting

Cellitinnen-NTC Neurologisches Therapiecentrum /ID# 277865

Cologne, North Rhine-Westphalia, Germany

Recruiting

Klinikum Lippe Detmold /ID# 279451

Detmold, North Rhine-Westphalia, Germany

Recruiting

Klinikum Dortmund Klinikzentrum Mitte /ID# 280222

Dortmund, North Rhine-Westphalia, Germany

Recruiting

Universitaetsklinikum Carl Gustav Carus Dresden /ID# 274167

Dresden, Saxony, Germany

Recruiting

Krankenhaus Martha-Maria Halle-Dolau /ID# 274174

Halle, Saxony-Anhalt, Germany

Recruiting

Praxis MD Oehlwein /ID# 274222

Gera, Thuringia, Germany

Recruiting

Asklepios Fachklinikum Stadtroda /ID# 274162

Stadtroda, Thuringia, Germany

Recruiting

Klinikum Bremen-Nord /ID# 275822

Bremen, Germany

Recruiting

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.